BRPI0819295A2 - Sistema para liberação em uma célula xcr1 positiva e usos do mesmo - Google Patents
Sistema para liberação em uma célula xcr1 positiva e usos do mesmoInfo
- Publication number
- BRPI0819295A2 BRPI0819295A2 BRPI0819295A BRPI0819295A2 BR PI0819295 A2 BRPI0819295 A2 BR PI0819295A2 BR PI0819295 A BRPI0819295 A BR PI0819295A BR PI0819295 A2 BRPI0819295 A2 BR PI0819295A2
- Authority
- BR
- Brazil
- Prior art keywords
- xcr1
- releasing
- positive
- cell
- xcr1 cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07022471A EP2062592A1 (en) | 2007-11-20 | 2007-11-20 | System for delivery into a XCR1 positive cell and uses thereof |
US1326307P | 2007-12-12 | 2007-12-12 | |
PCT/EP2008/009758 WO2009065561A2 (en) | 2007-11-20 | 2008-11-19 | System for delivery into a xcr1 positive cell and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0819295A2 true BRPI0819295A2 (pt) | 2015-05-05 |
Family
ID=39267731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0819295 BRPI0819295A2 (pt) | 2007-11-20 | 2008-11-19 | Sistema para liberação em uma célula xcr1 positiva e usos do mesmo |
Country Status (9)
Country | Link |
---|---|
US (1) | US10703817B2 (pt) |
EP (2) | EP2062592A1 (pt) |
JP (2) | JP2011503219A (pt) |
CN (1) | CN101896191B (pt) |
AU (1) | AU2008328183B2 (pt) |
BR (1) | BRPI0819295A2 (pt) |
CA (1) | CA2705588A1 (pt) |
MX (1) | MX2010005451A (pt) |
WO (1) | WO2009065561A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011097480A1 (en) * | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
MY166152A (en) | 2011-09-01 | 2018-06-06 | Eisai R&D Man Co Ltd | Anti-human xcr1 antibodies |
AU2012311238A1 (en) * | 2011-09-23 | 2014-04-17 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
WO2013070324A1 (en) | 2011-11-07 | 2013-05-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
US20130245236A1 (en) * | 2012-03-15 | 2013-09-19 | Richard Kroczek | Antibodies to the chemokine receptor xcr1 |
AU2015233542B2 (en) * | 2014-03-17 | 2020-01-16 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Prasidenten | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response |
WO2016032334A1 (en) * | 2014-08-28 | 2016-03-03 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations |
KR101833971B1 (ko) | 2016-02-19 | 2018-03-02 | 사회복지법인 삼성생명공익재단 | 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물 |
CN105622762B (zh) * | 2016-03-03 | 2020-04-03 | 中国农业科学院兰州兽医研究所 | 一种牛趋化因子介导的o型口蹄疫靶向性复合表位蛋白及疫苗 |
CN105777909B (zh) * | 2016-03-03 | 2020-04-03 | 中国农业科学院兰州兽医研究所 | 一种猪趋化因子介导的a型口蹄疫靶向性复合表位蛋白及疫苗 |
CN107056932B (zh) * | 2016-12-24 | 2021-04-09 | 深圳大学 | 一种氨基酸序列、含ova表位的融合蛋白及其制备方法和应用 |
US11905525B2 (en) * | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
US10815520B2 (en) | 2017-04-07 | 2020-10-27 | University Of Louisville Research Foundation, Inc. | Nanovesicles, methods, and systems for diagnosis and prognosis of cancer |
JP2021529535A (ja) * | 2018-07-02 | 2021-11-04 | ピュアテック エルワイティー, インコーポレイテッド | 生物学的薬剤の送達に使用する乳小胞 |
WO2020127277A1 (en) | 2018-12-18 | 2020-06-25 | Robert Koch-Institut | A peptide-loaded mhc-i presenting cell and an il-2 with extended half-life for amplifying a cellular cytotoxic immune response |
CN113412123A (zh) * | 2018-12-28 | 2021-09-17 | 豪夫迈·罗氏有限公司 | 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白 |
CN109609505A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院成都生物研究所 | 一种体内筛选的剪切rna的锤头状核酶 |
CN115551537A (zh) | 2019-12-03 | 2022-12-30 | 纽沃进公司 | 肿瘤细胞疫苗 |
CN113072647B (zh) * | 2021-06-04 | 2021-08-13 | 诺未科技(北京)有限公司 | 靶向人乳头瘤病毒的核酸疫苗 |
CN113072646A (zh) * | 2021-06-04 | 2021-07-06 | 北京承诺未来科技有限公司 | 靶向egfr的肿瘤核酸疫苗 |
WO2024015955A2 (en) * | 2022-07-15 | 2024-01-18 | President And Fellows Of Harvard College | Mucispirillum compositions and cancer treatment methods thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5780268A (en) * | 1995-12-06 | 1998-07-14 | Incyte Pharmaceuticals | Chemokine expressed in a mixed lymphocyte reaction |
US6395268B1 (en) * | 1996-10-24 | 2002-05-28 | Schering Corporation | Lymphotactin uses |
US6153182A (en) * | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
US7157418B1 (en) * | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
EP1346731B1 (en) * | 1998-07-22 | 2006-12-06 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
AU770802B2 (en) | 1998-10-21 | 2004-03-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Virus-like particles for the induction of autoantibodies |
US20030124627A1 (en) * | 2001-11-29 | 2003-07-03 | Burmer Glenna C. | Diagnostic and therapeutic compositions and methods related to chemokine (C motif ) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR) |
KR100442963B1 (ko) * | 2001-12-29 | 2004-08-04 | 주식회사 하이닉스반도체 | 고순도의 금속막 제조방법 |
US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
US20050136033A9 (en) * | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
EP1698902A1 (en) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Use of XCR1 for diagnosing or monitoring of immune tolerance |
-
2007
- 2007-11-20 EP EP07022471A patent/EP2062592A1/en not_active Withdrawn
-
2008
- 2008-11-19 CA CA2705588A patent/CA2705588A1/en not_active Abandoned
- 2008-11-19 BR BRPI0819295 patent/BRPI0819295A2/pt not_active Application Discontinuation
- 2008-11-19 US US12/741,798 patent/US10703817B2/en active Active
- 2008-11-19 CN CN200880117058.7A patent/CN101896191B/zh active Active
- 2008-11-19 AU AU2008328183A patent/AU2008328183B2/en active Active
- 2008-11-19 WO PCT/EP2008/009758 patent/WO2009065561A2/en active Application Filing
- 2008-11-19 JP JP2010534403A patent/JP2011503219A/ja active Pending
- 2008-11-19 EP EP08852540.7A patent/EP2200633B1/en active Active
- 2008-11-19 MX MX2010005451A patent/MX2010005451A/es active IP Right Grant
-
2014
- 2014-07-23 JP JP2014150090A patent/JP5946494B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP5946494B2 (ja) | 2016-07-06 |
US20100310562A1 (en) | 2010-12-09 |
JP2015007052A (ja) | 2015-01-15 |
AU2008328183A1 (en) | 2009-05-28 |
AU2008328183B2 (en) | 2013-12-12 |
CN101896191B (zh) | 2017-08-25 |
US10703817B2 (en) | 2020-07-07 |
WO2009065561A3 (en) | 2009-09-03 |
JP2011503219A (ja) | 2011-01-27 |
EP2062592A1 (en) | 2009-05-27 |
CN101896191A (zh) | 2010-11-24 |
EP2200633A2 (en) | 2010-06-30 |
WO2009065561A8 (en) | 2010-06-10 |
WO2009065561A2 (en) | 2009-05-28 |
EP2200633B1 (en) | 2018-05-23 |
MX2010005451A (es) | 2010-08-09 |
CA2705588A1 (en) | 2009-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0819295A2 (pt) | Sistema para liberação em uma célula xcr1 positiva e usos do mesmo | |
BR112012009921A2 (pt) | métodos para reprogramar células e usos do mesmos | |
BRPI1011725A2 (pt) | método e sistema para direcionar uma resposta biológica localizada em um implante | |
BRPI0908983A2 (pt) | sistema e dispositvo de célula de combustível | |
BRPI1006922A2 (pt) | sistema para descarte de medicação | |
BRPI1012304A2 (pt) | sistema para auxílio de subida | |
BRPI0817335A2 (pt) | método e sistema para desviar uma célula de energia de um suprimento de energia | |
BRPI0810097A2 (pt) | Sistemas e métodos para separação de líquidos | |
BR112013008410A2 (pt) | sistema para uso em reparação tecidual | |
BRPI0813429A2 (pt) | sistema e método para uma mbms aperfeiçoada para uma transferência de pss | |
BRPI1009314A2 (pt) | sistema e método para armazenar e liberar energia | |
BRPI0814144A2 (pt) | Sistema e método para calibração automática | |
BRPI1006542A2 (pt) | sistema e método para detectar uma queda de um usuário | |
BRPI0817299A2 (pt) | Vacinas e componentes de vacina para inibição de células microbianas | |
BRPI0820253A2 (pt) | Sistema de sensoriamento, e, método para sensoriar uma mudança em uma propriedade de um material | |
DE112008000870B8 (de) | Brennstoffzellensystem | |
BRPI0924310A2 (pt) | sistema e método de gestao e arquivo de conteúdos escolares | |
BR112012003233A2 (pt) | sistema e reservatório de segurança para alimentação enteral | |
BRPI0918321A2 (pt) | sistema configurado para prover terapia de luz a um indivíduo enquanto o indivíduo dorme e método para prover terapia de luz a um indivíduo enquanto o indivíduo dorme | |
DE112008000649B8 (de) | Brennstoffzellensystem | |
BRPI0908003A2 (pt) | sistemas e métodos para o envio de terapia de radiação | |
BRPI0817505A2 (pt) | Sistema e método para replicação e sincronismo | |
BRPI0819117A2 (pt) | sistema de dispensação de composição de combustível, e, método para fornecer uma composição de combustível | |
BRPI0818858A2 (pt) | Sistema de atracamento e de ancoragem automatizado | |
DE602008000154D1 (de) | Brennstoffzellensystem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/28 (2006.01), A61K 38/19 (2006.01), A61K 3 |
|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B07E | Notice of approval relating to section 229 industrial property law | ||
B06T | Formal requirements before examination | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
B09B | Decision: refusal | ||
B09B | Decision: refusal |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |